Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
2024
‘Simple model’ helps identify melanoma recurrence
Appetite change, tiredness, lymph node enlargement, abdominal pain and shortness of breath were common with melanoma recurrence.
Melanoma Treatment Advances: Fianlimab and Cemiplimab Show Promise
A longer-term follow-up of a study evaluating fianlimab, an anti-LAG-3 agent, and cemiplimab (Libtayo), an anti-PD-1 agent, is being presented as a poster at this year’s European Society for Medical Oncology (ESMO) Congress.
Neoadjuvant Immunotherapy Superior to Targeted Therapy in Stage III Melanoma
The standard of care for resectable stage IIIB or greater melanoma has been neoadjuvant therapy, and new data shows that neoadjuvant immunotherapy provides a long-lasting benefit to these patients, particularly if they achieve a major pathological response (MPR), which is a complete response or a near complete pathological response.